Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03891264 · ClinicalTrials.gov registry record · Phase 4
Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT03891264: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03891264 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03891264, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
In this research, the study team will use brain imaging to evaluate the presence of neuroinflammation in the brains and spinal cords of patients with low back pain, and whether CBD effects levels of neuroinflammation. The efficacy of CBD use for low back pain treatment will also be evaluated by observing whether CBD administration will reduce neuroinflammation and low back pain symptoms.
Interventions
- DRUG Cannabidiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2020-11-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03891264
The ClinicalTrials.gov registry entry for NCT03891264 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cannabidiol is the first listed.
NCT03891264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03891264 about?
NCT03891264 is a clinical study titled "Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain". In this research, the study team will use brain imaging to evaluate the presence of neuroinflammation in the brains and spinal cords of patients with low back pain, and whether CBD effects levels of neuroinflammation. The efficacy of CBD use for low back pain treatment will also be evaluated by obse...
What is the current status of trial NCT03891264?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2019-11-13. Estimated completion is 2020-11-23.
What interventions are being tested in trial NCT03891264?
The interventions under investigation include: Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT03891264?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.